285 related articles for article (PubMed ID: 34567287)
1. Overview of omics biomarkers in pituitary neuroendocrine tumors to design future diagnosis and treatment strategies.
Aydin B; Caliskan A; Arga KY
EPMA J; 2021 Sep; 12(3):383-401. PubMed ID: 34567287
[TBL] [Abstract][Full Text] [Related]
2. Past, Present, and Future of Therapies for Pituitary Neuroendocrine Tumors: Need for Omics and Drug Repositioning Guidance.
Aydin B; Yildirim E; Erdogan O; Arga KY; Yilmaz BK; Bozkurt SU; Bayrakli F; Turanli B
OMICS; 2022 Mar; 26(3):115-129. PubMed ID: 35172108
[TBL] [Abstract][Full Text] [Related]
3. Epigenomic and transcriptomic landscaping unraveled candidate repositioned therapeutics for non-functioning pituitary neuroendocrine tumors.
Aydin B; Beklen H; Arga KY; Bayrakli F; Turanli B
J Endocrinol Invest; 2023 Apr; 46(4):727-747. PubMed ID: 36306107
[TBL] [Abstract][Full Text] [Related]
4. Clinical presentation and recurrence of pituitary neuroendocrine tumors: results from a single referral center in Colombia.
Jimenez-Canizales CE; Rojas W; Alonso D; Romero I; Tabares S; Veronesi Zuluaga LA; Modica R; Colao A
J Endocrinol Invest; 2023 Nov; 46(11):2275-2286. PubMed ID: 37002436
[TBL] [Abstract][Full Text] [Related]
5. Overview of the 2022 WHO Classification of Pituitary Tumors.
Asa SL; Mete O; Perry A; Osamura RY
Endocr Pathol; 2022 Mar; 33(1):6-26. PubMed ID: 35291028
[TBL] [Abstract][Full Text] [Related]
6. Muti-omics integration analysis revealed molecular network alterations in human nonfunctional pituitary neuroendocrine tumors in the framework of 3P medicine.
Wen S; Li C; Zhan X
EPMA J; 2022 Mar; 13(1):9-37. PubMed ID: 35273657
[TBL] [Abstract][Full Text] [Related]
7. Update on Current Evidence for the Diagnosis and Management of Nonfunctioning Pituitary Neuroendocrine Tumors.
Whyte E; Nezu M; Chik C; Tateno T
Endocrinol Metab (Seoul); 2023 Dec; 38(6):631-654. PubMed ID: 37964483
[TBL] [Abstract][Full Text] [Related]
8. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.
Mete O; Alshaikh OM; Cintosun A; Ezzat S; Asa SL
Endocr Pathol; 2018 Dec; 29(4):332-338. PubMed ID: 30215160
[TBL] [Abstract][Full Text] [Related]
9. A New Generation Somatostatin-Dopamine Analogue Exerts Potent Antitumoral Actions on Pituitary Neuroendocrine Tumor Cells.
Vázquez-Borrego MC; L-López F; Gálvez-Moreno MA; Fuentes-Fayos AC; Venegas-Moreno E; Herrera-Martínez AD; Blanco-Acevedo C; Solivera J; Landsman T; Gahete MD; Soto-Moreno A; Culler MD; Castaño JP; Luque RM
Neuroendocrinology; 2020; 110(1-2):70-82. PubMed ID: 31272096
[TBL] [Abstract][Full Text] [Related]
10. Aggressive nonfunctioning pituitary neuroendocrine tumors.
Portovedo S; Neto LV; Soares P; Carvalho DP; Takiya CM; Miranda-Alves L
Brain Tumor Pathol; 2022 Oct; 39(4):183-199. PubMed ID: 35725837
[TBL] [Abstract][Full Text] [Related]
11. Splicing Machinery is Dysregulated in Pituitary Neuroendocrine Tumors and is Associated with Aggressiveness Features.
Vázquez-Borrego MC; Fuentes-Fayos AC; Venegas-Moreno E; Rivero-Cortés E; Dios E; Moreno-Moreno P; Madrazo-Atutxa A; Remón P; Solivera J; Wildemberg LE; Kasuki L; López-Fernández JM; Gadelha MR; Gálvez-Moreno MA; Soto-Moreno A; Gahete MD; Castaño JP; Luque RM
Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31561558
[TBL] [Abstract][Full Text] [Related]
12. Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors.
Herrgott GA; Asmaro KP; Wells M; Sabedot TS; Malta TM; Mosella MS; Nelson K; Scarpace L; Barnholtz-Sloan JS; Sloan AE; Selman WR; deCarvalho AC; Poisson LM; Mukherjee A; Robin AM; Lee IY; Snyder J; Walbert T; Rosenblum M; Mikkelsen T; Bhan A; Craig J; Kalkanis S; Rock J; Noushmehr H; Castro AV
Neuro Oncol; 2022 Jul; 24(7):1126-1139. PubMed ID: 35212383
[TBL] [Abstract][Full Text] [Related]
13. Aggressive pituitary tumors (PitNETs).
Nishioka H
Endocr J; 2023 Mar; 70(3):241-248. PubMed ID: 36858483
[TBL] [Abstract][Full Text] [Related]
14. Annotation of pituitary neuroendocrine tumors with genome-wide expression analysis.
Tebani A; Jotanovic J; Hekmati N; Sivertsson Å; Gudjonsson O; Edén Engström B; Wikström J; Uhlèn M; Casar-Borota O; Pontén F
Acta Neuropathol Commun; 2021 Nov; 9(1):181. PubMed ID: 34758873
[TBL] [Abstract][Full Text] [Related]
15. Differential expression levels of β-catenin are associated with invasive behavior of both functional and non-functional pituitary neuroendocrine tumor (PitNET).
Taghavi SF; Ghorbani M; Panahi M; Nazem S; Karimi M; Salimi V; Tavakoli-Yaraki M
Mol Biol Rep; 2023 Aug; 50(8):6425-6434. PubMed ID: 37326745
[TBL] [Abstract][Full Text] [Related]
16. Clinical, Biological, Radiological Pathological and Immediate Post-Operative Remission of Sparsely and Densely Granulated Corticotroph Pituitary Tumors: A Retrospective Study of a Cohort of 277 Patients With Cushing's Disease.
Rak B; Maksymowicz M; Pękul M; Zieliński G
Front Endocrinol (Lausanne); 2021; 12():672178. PubMed ID: 34135861
[TBL] [Abstract][Full Text] [Related]
17. Biguanides Exert Antitumoral Actions in Pituitary Tumor Cells Through AMPK-Dependent and -Independent Mechanisms.
Vázquez-Borrego MC; Fuentes-Fayos AC; Herrera-Martínez AD; L-López F; Ibáñez-Costa A; Moreno-Moreno P; Alhambra-Expósito MR; Barrera-Martín A; Blanco-Acevedo C; Dios E; Venegas-Moreno E; Solivera J; Gahete MD; Soto-Moreno A; Gálvez-Moreno MA; Castaño JP; Luque RM
J Clin Endocrinol Metab; 2019 Aug; 104(8):3501-3513. PubMed ID: 30860580
[TBL] [Abstract][Full Text] [Related]
18. Pituitary Tumors: Genetic and Molecular Factors Underlying Pathogenesis and Clinical Behavior.
Spada A; Mantovani G; Lania AG; Treppiedi D; Mangili F; Catalano R; Carosi G; Sala E; Peverelli E
Neuroendocrinology; 2022; 112(1):15-33. PubMed ID: 33524974
[TBL] [Abstract][Full Text] [Related]
19. Statins Directly Regulate Pituitary Cell Function and Exert Antitumor Effects in Pituitary Tumors.
Vázquez-Borrego MC; Fuentes-Fayos AC; Herrera-Martínez AD; Venegas-Moreno E; L-López F; Fanciulli A; Moreno-Moreno P; Alhambra-Expósito MR; Barrera-Martín A; Dios E; Blanco-Acevedo C; Solivera J; Granata R; Kineman RD; Gahete MD; Soto-Moreno A; Gálvez-Moreno MA; Castaño JP; Luque RM
Neuroendocrinology; 2020; 110(11-12):1028-1041. PubMed ID: 31940630
[TBL] [Abstract][Full Text] [Related]
20. Silent somatotropinomas.
Lamas C; García-Martínez A; Cámara R; Fajardo-Montanana C; Viguera L; Aranda I
Minerva Endocrinol; 2019 Jun; 44(2):137-142. PubMed ID: 30531696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
